The significant drop in Vaxxinity's stock price is directly related to the announcement of its delisting from Nasdaq. This move is perceived negatively by the market as it reflects compliance issues and potential challenges in capital raising and investor attraction. The transition to over-the-counter trading typically results in reduced visibility and liquidity, which can further impact investor sentiment and stock performance in the short term.